The breast international group 1-98 trial: Big results for women with hormone-sensitive early breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 5, 2007, Pages 627-634

  Monnier, Alain M ^a  

^a Centre Hospitalier General Andre Boulloche   (France)

Author keywords

Anastrozole; Aromatase inhibitor; Disease free survival; Hormone sensitive breast cancer; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; POSTOPERATIVE PERIOD; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 34248550585     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.5.627     Document Type: Article

References (47)

1. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738-2746 (1996).
2. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J. Clin. Oncol. 23(16S), 62s (2005) (Abstract 738).
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
4. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
5. Baum M, Budzar AU, Cuzick J et al; for the ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002). Erratum in: Lancet 360, 1520 (2002).
6. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004). Erratum in: N. Engl. J. Med. 351, 2461 (2004).
7. Thürlimann B, Keshaviah A, Coates AS et al. for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med 353, 2747-2757 (2005).
8. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21, 2101-2109 (2003).
9. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
10. Goldhirsch A, Gelber RD, Coates AS. What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? Nat. Clin. Pract. Oncol. 2, 440-441 (2005).
11. Letrozole (Femara) summary of product characteristics. Novartis Pharmaceuticals AG, Basel, Switzerland (2006).
12. Letrozole (Femara) package insert. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA (2005).
13. Geisler J, Ekse D, Helle H, Eystein Lønning P. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res. Treat. 100(Suppl. 1), S23 (2006) (Abstract 103).
14. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol. 24(18S), 15s (2006) (Abstract 552).
15. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer Ann. Oncol. 17(Suppl. 9), ix100 (2006) (Abstract 265P).
16. Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 39, 2318-2327 (2003).
17. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19, 3808-3816 (2001).
18. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106, 2095-2103 (2006).
19. Smith IE, Dowsett M, Ebbs SR et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5116 (2005).
20. Dowsett M, A'Hern R, Smith I; on behalf of the IMPACT Trialists. Ki67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2005) (Abstract 45).
21. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63, 6523-6531 (2003).
22. De Boer R Sr, Burris HA, Monnier A et al.; on behalf of the H2H trial steering committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J. Clin. Oncol. 24(18s), 582s (2006) (Abstract 10672).
23. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25(5), 486-492 (2007).
24. Anastrozole (Arimidex) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA (2005).
25. Howell A, Cuzick J, Baum M et al. ATAC Trialists' Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
26. Mauriac L, Keshaviah A, Debled M et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Ann. Oncol. (Epub ahead of print) (2007).
27. Houghton J; on behalf of the ATAC Trialists' Group. Initial adjuvant therapy with ANA (S) reduced rates of early breast cancer recurrent and adverse events compared with TAM (T)-data reported on behalf of the ATAC ('Arimidex', TAM, Alone or in Combination) Trialists' group. Ann. Oncol. 17(Suppl. 9), ix93 (2006) (Abstract 243PD).
28. Viale G, Regan M, Dell'Orto P et al; The BIG 1-98 Collaborative International Breast Cancer Study Group. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2005) (Abstract 44).
29. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 23, 7512-7517 (2005).
30. Dowsett M, Allred DC; on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res. Treat. 100(Suppl. 1), S21 (2006) (Abstract 48).
31. Mansell J, Monypenny IJ, Skene AI et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res. Treat 100(Suppl. 1), S111 (2006) (Abstract 2091).
32. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 24, 5305-5312 (2006).
33. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 25(7), 829-836 (2007).
34. Bundred N, Campbell I, Coleman R et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur. J. Cancer 4(Suppl.), 48 (2006) (Abstract 12).
35. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 192, 496-498 (2006).
36. Presant C, Kelly C, Bosserman L et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice. J. Clin. Oncol. 24(18S), 334s (2006) (Abstract 6137).
37. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97, 1262-1271 (2005).
38. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole an serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol. 16, 707-715 (2005).
39. Perez E. The balance between risks and benefits: long-term use of aromatase inhibitors. Eur. J. Cancer 4 (Suppl.), 16-25 (2006).
40. Monnier A. Comparing AI cardiovascular safety data: trial comparators and outcomes. Ann. Oncol. 17(Suppl. 9), ix100 (2006) (Abstract 266P).
41. ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment of early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7, 633-643 (2006).
42. Coombes RC, Paridaens R, Jassem J; for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study. Lancet 369(9561), 559-570 (2007).
43. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352, 1965-1969 (1998). Erratum in: Lancet 353, 330 (1999).
44. Vakaet L, Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM in postmenopausal women with early breast cancer (EBC). Breast Cancer Res. Treat. 100(Suppl. 1), S108-S109 (2006) (Abstract 2084).
45. Moy B, Elliott CR, Chapman J-AW, Pater JL, Ding Z, Goss PE. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Res. Treat. 100(Suppl. 1), S144 (2006) (Abstract 3059).
46. Mamounas EP, Lembersky B, Jeong JH et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin. Breast Cancer 7(5), 416-421 (2006).
47. Jones SE. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials. Clin. Breast Cancer 6(Suppl. 2), S41-S44 (2006).